Head of mRNA Platform

Organization: Platform Technology

Location: Singapore

Job Type: Senior Leadership | Full Time

About NATi

The Nucleic Acid Therapeutics Initiative (NATi), hosted by A*STAR, is Singapore's national platform dedicated to advancing RNA-based medicines and revolutionizing drug and vaccine development. NATi's mission is to establish Singapore as a globally recognized hub of excellence in nucleic acid therapeutics research, clinical translation, and commercialization.

NATi focuses on key RNA modalities such as antisense oligonucleotides (ASOs), small interfering RNA (siRNA), and messenger RNA (mRNA). To drive this vision, NATi is building a biotech-like translational engine focused on asset and technology development spanning discovery to clinical development.

We are actively seeking passionate and committed RNA scientists with deep translational expertise to join us in advancing the next generation of RNA-based therapeutics.

Position Overview

The Head of mRNA Platform will build and lead a robust and fully integrated mRNA research organization to support the discovery, production, preclinical development, and translation of mRNA Drug Candidates. This role demands deep expertise across the different elements of the mRNA technology to ensure readiness and to position the platform to operate as a robust engine for development of mRNA-based medicines.

This leader will work closely with the NATi Managing Director to develop and execute the strategy for the mRNA Platform. They will establish productive partnerships with the heads of therapeutic areas to collaboratively develop the next wave of mRNA medicines.

Additionally, this leader will play a critical role in defining the innovation agenda for the mRNA platform and oversee strategic partnerships with global collaborators focused on unlocking the full potential of mRNA as a therapeutic modality.

Key Responsibilities

• Develop and implement the R&D roadmap for the mRNA technology platform, supporting discovery, optimization, preclinical development, and production of mRNA drug candidates.
• Build and lead a high-performing scientific team accountable for mRNA design, IVT/process development, LNP formulation, targeted delivery, analytical characterization, and CMC development.
• Oversee the evaluation, prioritization, and adoption of novel technologies to enhance platform capabilities and support pipeline expansion beyond established routes of administration and therapeutic indications.
• Collaborate effectively with heads of therapeutic areas within NATi to develop a robust pipeline of mRNA assets on an accelerated timeline with optimal resource utilization.
• Establish public-private partnerships, fostering joint development programs and strategic alliances.
• Represent the mRNA platform at global scientific conferences, reinforcing NATi's leadership in next-generation RNA therapeutics.
• Engage with regulatory agencies to ensure alignment on safety, efficacy, scalability, and regulatory compliance of NATi's mRNA platform capabilities.

Qualifications & Experience

• A doctorate degree in Biology, Chemistry, Engineering, or a related field.
• A minimum of 12+ (Executive Director), 15+ (Associate Vice President), 18+ (Vice President) years of experience in development/optimization of mRNA technology and its utilization in drug development within pharmaceutical or biotech organizations.
• Proven track record in mRNA-based technology innovation and asset generation demonstrated by contribution to IP, IND filings, and other public disclosures.
• Demonstrated experience in organizational leadership and R&D governance.

Global Recruitment & Competitive Compensation

NATi is conducting a global search for top-tier talent in mRNA therapeutics. We welcome applications from leading scientists and biotech innovators worldwide.

This role provides a highly competitive compensation package aligned with global industry standards, including attractive benefits and long-term career growth opportunities within Singapore's thriving ecosystem. Join us in shaping the future of RNA-based medicines and establishing Singapore as a world-class hub for nucleic acid therapeutics

#J-18808-Ljbffr

---